Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy

Table 1

Demographics characteristics and per group treatment characteristics ().

Demographics characteristics and per group treatment baselines, per protocol population
	Pregabalin		Combined gabapentin		value
		%		%
Gender
Female	74	60.2; 95% CI; (51.4–68.9)	100	68.0; 95% CI; (60.4–75.7)	0.179
Male	49	39.8; 95% CI; (31.1–48.6)	47	32.0; 95% CI; (24.3–39.6)
Age (years)
Average	53.6		52.5		0.344
Std. deviation	9.4		10.5
Minimum–maximum	25.0–71.0		19.0–70.0
Risk factors
Smoking
Yes	8	6.5; 95% CI; (2.1–10.9)	13	8.8; 95% CI; (4.2–13.5)	0.475
Arterial hypertension
History	42	34.1; 95% CI; (25.6–42.6)	58	39.4; 95% CI; (31.5–47.4)	0.369
Hypothyroidism
History	1	0.8; 95% CI; (0.0–2.4)	1	0.7; 95% CI; (0.0–2.0)	0.900
Cholesterol (baseline measure)
Average	198.3		195.2		0.560
Std. deviation	47.5		38.3
Minimum–maximum	101.0–542.0		71.0–366.0
Triglycerides (baseline measure)
Average	207.7		189.9		0.352
Std. deviation	183.4		116.3
Minimum–maximum	53.0–1390.0		63.0–952.0
BMI (Kg/m^2)
Average	28.2		27.9		0.610
Std. deviation	3.9		4.1
Minimum–maximum	18.4–39.4		17.4–39.4
Diabetes duration
Average	9.8		9.5		0.765
Std. deviation	5.9		6.5
Minimum–maximum	1.5–25.5		1.4–32.0
With diabetic neuropathic
Average	2.9		2.8		0.603
Std. deviation	1.1		1.1
Minimum–maximum	0.6–5.9		1.0–5.9
Diabetes treatment
Oral	100	81.3; 95% CI; (74.3–88.3)	112	76.2; 95% CI; (69.2–83.2)
Insulin	3	2.4; 95% CI; (0.0–5.2)	5	3.4; 95% CI; (0.4–6.2)	0.333
Both	20	16.3; 95% CI; (9.7–22.9)	30	20.4; 95% CI; (13.8–27.0)
Glucose (baseline)
Average	126.9		128.9		0.603
Std. deviation	53.0		51.2
Minimum–maximum	44.0–410.0		64.0–325.0
HbA1c
Average	7.4		7.4		0.603
Std. deviation	1.3		1.4
Minimum–maximum	5.2–10.2		4.9–10.0